Page last updated: 2024-10-14

danoprevir

Cross-References

ID SourceID
PubMed CID129010331
MeSH IDM0552073
PubMed CID11285588
CHEMBL ID258734
SCHEMBL ID2289034
MeSH IDM0552073

Synonyms (47)

Synonym
850876-88-9
danoprevir ,
HMS3654C18
itmn-191;r7227;ro5190591;rg7227
itmn-191
rg7227
r7227 ,
r-05190591
ro5190591
CHEMBL258734
r05190591
ro-5190591
itmn 191
rg 7227
r 7227
911z9pcq5f ,
r 05190591
itmn191
itmn b
intermune itmn-191
danoprevir [usan:inn]
rg-7227
r7227 cpd
ganovo
unii-911z9pcq5f
S1183
danoprevir [usan]
danoprevir [who-dd]
danoprevir [inn]
MLS006011139
smr004702916
SCHEMBL2289034
(2r,6s,13as,14ar,16as,z)-6-(tert-butoxycarbonylamino)-14a-(cyclopropylsulfonylcarbamoyl)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-2-yl 4-fluoroisoindoline-2-carboxylate
rg7227, itmn-191, ro5190591
4-fluoro-1,3-dihydro-2h-isoindole-2-carboxylic acid (2r,6s,13as,14ar,16as)-14a-(((cyclopropylsulfonyl)amino)carbonyl)-6-(((1,1-dimet hylethoxy)carbonyl)amino)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a
J-515317
SW219089-1
DB11779
(2r,6s,13as,14ar,16as,z)-6-((tert-butoxycarbonyl)amino)-14a-((cyclopropylsulfonyl)carbamoyl)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-2-yl 4-fluoroisoindoline-2-carboxylate
[(1s,4r,6s,7z,14s,18r)-4-(cyclopropylsulfonylcarbamoyl)-14-[(2-methylpropan-2-yl)oxycarbonylamino]-2,15-dioxo-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-en-18-yl] 4-fluoro-1,3-dihydroisoindole-2-carboxylate
danoprevir (itmn-191)
danoprevir (rg7227,itmn-191,ro5190591
bdbm50495950
CCG-270417
Q27271364
NCGC00346498-06
AKOS037515841

Toxicity

ExcerptReference
" Two patients withdrew prematurely from study medications due to adverse events."( Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders.
Brennan, BJ; Gane, EJ; Kulkarni, R; Larrey, DG; Le Pogam, S; Morcos, PN; Nájera, I; Petric, R; Rouzier, R; Shulman, NS; Smith, P; Tran, JQ; Wiercinska-Drapalo, A; Yetzer, ES; Zhang, Y, 2014
)
" The secondary endpoint was virologic response rate at end-of-treatment and adverse event outcome."( Efficacy and safety of danoprevir plus sofosbuvir in GT 1, 2, 3, or 6 chronic hepatitis C patients with or without cirrhosis in China.
Feng, K; Huang, P; Ke, L; Lin, C; Liu, J; Pan, S; Yang, X; Zeng, Y, 2021
)

Pharmacokinetics

ExcerptReference
" Ritonavir, an HIV-1 protease inhibitor (PI) and potent CYP3A inhibitor, is used as a pharmacokinetic enhancer at subtherapeutic doses in combination with other HIV PIs."( Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug-drug interaction study.
Blotner, S; Chen, Y; Fretland, J; Haznedar, JO; Reddy, MB; Smith, P; Tran, JQ, 2012
)
" The clinical results demonstrate that low-dose ritonavir enhances the pharmacokinetic profile of low-dose danoprevir such that overall danoprevir exposures can be reduced while sustaining danoprevir trough concentrations."( Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug-drug interaction study.
Blotner, S; Chen, Y; Fretland, J; Haznedar, JO; Reddy, MB; Smith, P; Tran, JQ, 2012
)
" Blood samples were collected serially with each dose for pharmacokinetic assessment."( Pharmacokinetics of a three-way drug interaction between danoprevir, ritonavir and the organic anion transporting polypeptide (OATP) inhibitor ciclosporin.
Asthappan, J; Brennan, BJ; Goelzer, P; Morcos, PN; Moreira, SA; Navarro, MT; Smith, PF; Weigl, P, 2013
)
"Open-label, two-period, single-sequence pharmacokinetic study."( Effect of ritonavir-boosted danoprevir, a potent hepatitis C virus protease inhibitor, on the pharmacokinetics of methadone in healthy subjects undergoing methadone maintenance therapy.
Bech, N; Brennan, BJ; Morcos, PN; Moreira, SA; Navarro, MT; Smith, PF, 2014
)
" Pharmacokinetic parameters for the total concentrations of (R)- and (S)-methadone on Days -1 and 10 were determined using noncompartmental methods."( Effect of ritonavir-boosted danoprevir, a potent hepatitis C virus protease inhibitor, on the pharmacokinetics of methadone in healthy subjects undergoing methadone maintenance therapy.
Bech, N; Brennan, BJ; Morcos, PN; Moreira, SA; Navarro, MT; Smith, PF, 2014
)
"Coadministration of DNVr with MMT resulted in no significant pharmacokinetic interactions or signs of methadone withdrawal."( Effect of ritonavir-boosted danoprevir, a potent hepatitis C virus protease inhibitor, on the pharmacokinetics of methadone in healthy subjects undergoing methadone maintenance therapy.
Bech, N; Brennan, BJ; Morcos, PN; Moreira, SA; Navarro, MT; Smith, PF, 2014
)
" DNV AUC0-∞, Cmax and C12h GMR% (90% CI) with ranitidine: 81."( Effect of meal and antisecretory agents on the pharmacokinetics of danoprevir/ritonavir in healthy volunteers.
Bech, N; Brennan, BJ; Morcos, PN; Moreira, SA; Navarro, MT; Quatkemeyer, A; Smith, PF, 2014
)

Compound-Compound Interactions

Danoprevir (RG7227) is a potent macrocyclic inhibitor of the hepatitis C virus NS3/4A protease. It is currently in development in combination with low-dose ritonavir.

ExcerptReference
"The safety and antiviral efficacy of danoprevir was examined over 14 days in combination with pegylated interferon α-2a (180 μg once weekly) and ribavirin (1000-1200 mg/day) in a double-blind, placebo-controlled, phase 1b, multiple ascending dose study consisting of 6 dose cohorts (400 mg, 600 mg, and 900 mg twice daily and 100 mg, 200 mg, and 300 mg 3 times daily)."( Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis C.
Bradford, W; Forestier, N; Guyader, D; Larrey, D; Lim, S; Marcellin, P; Patat, A; Porter, S; Qin, X; Rouzier, R; Seiwert, SD; Smith, PF; Zeuzem, S, 2011
)
"Danoprevir in combination with pegylated interferon α-2a and ribavirin was safe and generally well tolerated."( Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis C.
Bradford, W; Forestier, N; Guyader, D; Larrey, D; Lim, S; Marcellin, P; Patat, A; Porter, S; Qin, X; Rouzier, R; Seiwert, SD; Smith, PF; Zeuzem, S, 2011
)
"Our study showed substantial antiviral efficacy of danoprevir in combination with pegylated interferon α-2a and ribavirin."( Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis C.
Bradford, W; Forestier, N; Guyader, D; Larrey, D; Lim, S; Marcellin, P; Patat, A; Porter, S; Qin, X; Rouzier, R; Seiwert, SD; Smith, PF; Zeuzem, S, 2011
)
" Ritonavir, an HIV-1 protease inhibitor (PI) and potent CYP3A inhibitor, is used as a pharmacokinetic enhancer at subtherapeutic doses in combination with other HIV PIs."( Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug-drug interaction study.
Blotner, S; Chen, Y; Fretland, J; Haznedar, JO; Reddy, MB; Smith, P; Tran, JQ, 2012
)
" Following results from this drug-drug interaction (DDI) model, a crossover study was performed in healthy volunteers to investigate the effects of acute and repeat dosing of low-dose ritonavir on danoprevir single-dose pharmacokinetics."( Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug-drug interaction study.
Blotner, S; Chen, Y; Fretland, J; Haznedar, JO; Reddy, MB; Smith, P; Tran, JQ, 2012
)
"Danoprevir (RG7227) is a potent macrocyclic inhibitor of the hepatitis C virus NS3/4A protease, which is currently in development in combination with low-dose ritonavir for the treatment of chronic hepatitis C infection."( Pharmacokinetics of a three-way drug interaction between danoprevir, ritonavir and the organic anion transporting polypeptide (OATP) inhibitor ciclosporin.
Asthappan, J; Brennan, BJ; Goelzer, P; Morcos, PN; Moreira, SA; Navarro, MT; Smith, PF; Weigl, P, 2013
)
" In the first period, subjects were randomized to receive either a single oral dose of danoprevir 100 mg in combination with ritonavir 100 mg or a single oral dose of ciclosporin 100 mg."( Pharmacokinetics of a three-way drug interaction between danoprevir, ritonavir and the organic anion transporting polypeptide (OATP) inhibitor ciclosporin.
Asthappan, J; Brennan, BJ; Goelzer, P; Morcos, PN; Moreira, SA; Navarro, MT; Smith, PF; Weigl, P, 2013
)
"A significant drug-drug interaction was observed between ciclosporin and danoprevir/ritonavir, leading to substantial increases in exposure to danoprevir and a lesser impact on exposure to ritonavir."( Pharmacokinetics of a three-way drug interaction between danoprevir, ritonavir and the organic anion transporting polypeptide (OATP) inhibitor ciclosporin.
Asthappan, J; Brennan, BJ; Goelzer, P; Morcos, PN; Moreira, SA; Navarro, MT; Smith, PF; Weigl, P, 2013
)

Bioavailability

Danoprevir is a potent, highly selective, macrocyclic, orally bioavailable inhibitor of the hepatitis C virus protease. It is a substrate of cytochrome P450 (CYP) 3A. We administered five bRo5 substrates intravenously or orally to wild-type and Mdr1a, Bcrp, and MDr1a/Bcrp knockout rats.

ExcerptReference
" The observed relative bioavailability from intracolonic delivery in the monkey was approximately 30% relative to oral administration, consistent with the model prediction of 40%."( Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible.
Brennan, BJ; Connor, A; Evans, P; Fretland, A; McLawhon, P; Morcos, PN; Reddy, MB; Smith, P; Tran, JQ; Zhou, A, 2011
)
"Danoprevir is a potent, highly selective, macrocyclic, orally bioavailable inhibitor of the hepatitis C virus protease, and a substrate of cytochrome P450 (CYP) 3A."( Two-way interaction study between ritonavir boosted danoprevir, a potent HCV protease inhibitor, and ketoconazole in healthy subjects.
Brennan, BJ; Chang, L; Chung, D; Morcos, PN; Navarro, M; Smith, PF; Tran, JQ, 2014
)
" Absolute bioavailability of danoprevir 100 mg was low (1."( Characterization of the transmembrane transport and absolute bioavailability of the HCV protease inhibitor danoprevir.
Asthappan, J; Brennan, BJ; Funk, C; Goelzer, P; Morcos, PN; Moreira, S; Poirier, A; Portmann, R; Smith, PF, 2015
)
" We administered five bRo5 substrates (asunaprevir, cyclosporine, danoprevir, ledipasvir, and simeprevir) intravenously or orally to wild-type and Mdr1a, Bcrp, and Mdr1a/Bcrp knockout rats, calculated the clearance, oral bioavailability, and absorption rate profile of each substrate, and compared the results."( Estimating Efflux Transporter-Mediated Disposition of Molecules beyond the Rule of Five (bRo5) Using Transporter Gene Knockout Rats.
Miyake, T, 2020
)

Dosage Studied

The feasibility of a controlled release (CR) formulation to allow less frequent dosing was investigated using experimental approaches and physiological modeling. A crossover study was performed in healthy volunteers to investigate the effects of acute and repeat dosing of low-dose ritonavir on danoprevir single-dose pharmacokinetics.

ExcerptReference
" However, the pharmacist who prepared the doses, personnel involved in pharmacokinetic sample analyses, statisticians who prepared data summaries, and the clinical pharmacologists who reviewed the data before deciding to initiate dosing in the next cohort were not masked to treatment allocation."( Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.
Angus, PW; Baher, L; Berrey, MM; Bradford, W; Chu, T; Elston, R; Gane, EJ; Ipe, D; Laughlin, M; Lopatin, U; Morcos, PN; Najera, I; Ritchie, B; Roberts, SK; Shulman, NS; Smith, PF; Stedman, CA, 2010
)
" Therefore, the feasibility of a controlled release (CR) formulation to allow less frequent dosing was investigated using experimental approaches and physiological modeling to examine whether danoprevir is absorbed in the colon."( Physiological modeling and assessments of regional drug bioavailability of danoprevir to determine whether a controlled release formulation is feasible.
Brennan, BJ; Connor, A; Evans, P; Fretland, A; McLawhon, P; Morcos, PN; Reddy, MB; Smith, P; Tran, JQ; Zhou, A, 2011
)
" Clinical studies in HCV patients have shown a potential need for a high danoprevir daily dose and/or dosing frequency."( Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug-drug interaction study.
Blotner, S; Chen, Y; Fretland, J; Haznedar, JO; Reddy, MB; Smith, P; Tran, JQ, 2012
)
" Following results from this drug-drug interaction (DDI) model, a crossover study was performed in healthy volunteers to investigate the effects of acute and repeat dosing of low-dose ritonavir on danoprevir single-dose pharmacokinetics."( Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug-drug interaction study.
Blotner, S; Chen, Y; Fretland, J; Haznedar, JO; Reddy, MB; Smith, P; Tran, JQ, 2012
)
"A total of 54 patients infected with hepatitis C virus genotype 1 received an oral drug cocktail (2 mg midazolam, 10 mg warfarin and 10 mg vitamin K) before and after 14 days of dosing with either danoprevir/r or placebo plus low-dose ritonavir (placebo/r)."( A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail.
Brennan, BJ; Chang, L; Giraudon, M; Kulkarni, R; Morcos, PN; Shulman, N; Smith, PF; Tran, JQ, 2013
)
" No dosage adjustment is needed for MMT when coadministered with DNVr."( Effect of ritonavir-boosted danoprevir, a potent hepatitis C virus protease inhibitor, on the pharmacokinetics of methadone in healthy subjects undergoing methadone maintenance therapy.
Bech, N; Brennan, BJ; Morcos, PN; Moreira, SA; Navarro, MT; Smith, PF, 2014
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (9)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Genome polyprotein IC50 (µMol)0.00020.00000.02890.1870AID1645923
NS3 protease Ki0.04480.00390.08290.2000AID1070607
Non-structural protein 4A IC50 (µMol)0.00020.00000.02890.1870AID1645923
NS3 protease Hepatitis C virus subtype 1bKi0.00900.00901.26706.1000AID1299188
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 1A2Homo sapiens (human)INH25.00000.10000.10000.1000AID1070637
Cytochrome P450 3A4Homo sapiens (human)INH12.00001.70002.85004.0000AID1070633
Cytochrome P450 2D6Homo sapiens (human)INH25.00003.20003.40003.6000AID1070634
Cytochrome P450 2C9 Homo sapiens (human)INH25.00004.40007.00009.1000AID1070636
Cytochrome P450 2C19Homo sapiens (human)INH25.00007.00007.00007.0000AID1070635
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (42)

Processvia Protein(s)Taxonomy
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2C19Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C19Homo sapiens (human)
steroid metabolic processCytochrome P450 2C19Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C19Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C19Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (34)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
iron ion bindingCytochrome P450 2C19Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxygen bindingCytochrome P450 2C19Homo sapiens (human)
enzyme bindingCytochrome P450 2C19Homo sapiens (human)
heme bindingCytochrome P450 2C19Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
aromatase activityCytochrome P450 2C19Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C19Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C19Homo sapiens (human)
plasma membraneCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
cytoplasmCytochrome P450 2C19Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (164)

Assay IDTitleYearJournalArticle
AID1071918Inhibition of Hepatitis C virus genotype 1b full-length NS3/NS4A protease assessed as equilibrium dissociation constant by surface plasmon resonance biosensor-based interaction kinetic analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID711502Inhibition of HCV 1b NS3 protease2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
AID1070641Antiviral activity against Hepatitis C virus genotype 2 infected in human HuH7 cells assessed as decrease in replicon RNA level after 2 days by TaqMan Gold RT-PCR analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID719472Antiviral activity against HCV subtype 1b expressing wild type NS3/4A protease infected in ET cells after 72 hrs2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups.
AID1698001Lipophilicity, log D of the compound at pH 7.4 by by shake flask method
AID584109Ratio of EC50 for wild type HCV1b harboring NS3 protease gene to EC50 for HCV1b harboring NS3 protease Q80K mutant2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.
AID656670Antiviral activity against Hepatitis C virus genotype 1b expressing wild type NS3/4A protease infected in HuH7 cells2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease.
AID1070636Inhibition of CYP2C9 (unknown origin)2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID539678Inhibition of HCV 1a NS3/4A protease by FRET assay2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease.
AID1071916Inhibition of Hepatitis C virus genotype 3a full-length NS3 protease assessed as equilibrium dissociation constant by surface plasmon resonance biosensor-based interaction kinetic analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID1070621Metabolic stability in human hepatocytes assessed as extraction ratio at 1 uM2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1070622Metabolic stability in rat hepatocytes assessed as extraction ratio at 1 uM2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1070635Inhibition of CYP2C19 (unknown origin)2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID584110Ratio of EC50 for wild type HCV1b harboring NS3 protease gene to EC50 for HCV1b harboring NS3 protease Q80K, T54S mutant2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.
AID538710Antiviral activity against HCV genotype 1b transfected in human hepatoma cell assessed as inhibition of viral replication2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease.
AID1071913Inhibition of Hepatitis C virus genotype 1b full-length NS3 protease assessed as overall/observed affinity by surface plasmon resonance biosensor-based interaction kinetic analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID656676Antiviral activity against Hepatitis C virus genotype 1b expressing NS3/4A protease R155K mutant infected in HuH7 cells2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease.
AID521266Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 D168V mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID664168Resistance index, ratio of EC50 for Hepatitis C virus subtype 1b harboring protease D168A mutant to EC50 for wild type Hepatitis C virus subtype 1b2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID539674Metabolic absorption in rat2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease.
AID1070640Antiviral activity against Hepatitis C virus genotype 1b infected in human HuH7 cells assessed as decrease in replicon RNA level after 2 days by TaqMan Gold RT-PCR analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID719471Antiviral activity against HCV subtype 1b expressing NS3/4A A156S mutant protease infected in ET cells after 72 hrs2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups.
AID538713Metabolic absorption in Sprague-Dawley rat at 5 mg/kg, po2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease.
AID664167Antiviral activity against Hepatitis C virus subtype 1b harboring protease R155K mutant by transient replicon assay2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID1070602Ratio of EC50 for Hepatitis C virus harboring NS3/4A protease A156T mutant gene to EC50 for Hepatitis C virus harboring wild type NS3/4A protease infected in human HuH7 cells2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID711501Inhibition of HCV 1a NS3 protease2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
AID538708Inhibition of HCV genotype 1 a NS3/4A protease by FRET assay2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease.
AID1070616Aqueous solubility of the compound at pH 6.5 by modified shake-flask method2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1299190Cytotoxicity against human HuH7 cells2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Discovery of pyrazinone based compounds that potently inhibit the drug-resistant enzyme variant R155K of the hepatitis C virus NS3 protease.
AID656673Antiviral activity against Hepatitis C virus genotype 1b expressing NS3/4A protease A156V mutant infected in HuH7 cells2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease.
AID711500Antiviral activity against HCV by cell based replicon assay2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
AID1071914Inhibition of Hepatitis C virus genotype 1a full-length NS3/NS4A protease assessed as overall/observed affinity by surface plasmon resonance biosensor-based interaction kinetic analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID521264Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 V170A mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID1070613Plasma clearance in rat assessed as extraction ratio2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID664166Antiviral activity against wild type Hepatitis C virus subtype 1b by transient replicon assay2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID656668Antiviral activity against Hepatitis C virus genotype 1b infected in HuH7 cells2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease.
AID719466Antiviral activity against HCV subtype 1b expressing NS3/4A R115K mutant protease infected in ET cells after 72 hrs2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups.
AID322946Inhibition of HCV NS3 protease by FRET assay2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Hepatitis C virus NS3 protease inhibitors comprising a novel aromatic P1 moiety.
AID322947Antiviral activity against Hepatitis C virus infected human hepatoma cells by replicon assay2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
Hepatitis C virus NS3 protease inhibitors comprising a novel aromatic P1 moiety.
AID521268Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 A156S mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID584103Ratio of EC50 for wild type HCV1b harboring NS3 protease gene to EC50 for HCV1b A25 harboring NS3 protease T40A, T54S, V55I, I64L, P67S, Q80K, Q88H, S90A, L153I mutant2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.
AID656669Antiviral activity against Hepatitis C virus genotype 1a infected in HuH7 cells2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease.
AID1071915Inhibition of Hepatitis C virus genotype 1a full-length NS3 protease assessed as overall/observed affinity by surface plasmon resonance biosensor-based interaction kinetic analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID538714Oral bioavailability in Sprague-Dawley rat at 5 mg/kg2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease.
AID612410Inhibition of HCV NS3 protease2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
P2-P1' macrocyclization of P2 phenylglycine based HCV NS3 protease inhibitors using ring-closing metathesis.
AID584102Antiviral activity against HCV1b Con1 harboring NS3 protease gene infected in human Huh7/Lunet cells assessed as inhibition of viral replication after 3 days by luciferase based transient-transfection assay2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.
AID1698007Ratio of drug level in human blood to plasma administered through iv dosing by LC-MS/MS analysis
AID1070612Volume of distribution at steady state in Sprague-Dawley rat at 30 mg/kg, po by HPLC-MS/MS analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1070631Time-dependent inhibition of CYP3A4 (unknown origin)2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1071917Inhibition of Hepatitis C virus genotype 1b NS3 protease domain assessed as equilibrium dissociation constant by surface plasmon resonance biosensor-based interaction kinetic analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID1070605Antiviral activity against Hepatitis C virus genotype 1a isolate Con1 harboring NS3/4A protease A156T mutant gene infected in human HuH7 cells assessed as inhibition of HCV replicon replication by luciferase assay2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1070647Inhibition of Hepatitis C virus genotype 1b NS3/4A protease using Ac-DE-Dap(QXL520)-EE-Abu-psi-[COO]-AS-Cys(5-FAMsp)-NH2 as substrate by FRET analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID664169Resistance index, ratio of EC50 for Hepatitis C virus subtype 1b harboring protease D168V mutant to EC50 for wild type Hepatitis C virus subtype 1b2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID1070648Inhibition of Hepatitis C virus genotype 1a NS3/4A protease using Ac-DE-Dap(QXL520)-EE-Abu-psi-[COO]-AS-Cys(5-FAMsp)-NH2 as substrate by FRET analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1070632Time-dependent induction of CYP3A4 (unknown origin)2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1070606Antiviral activity against Hepatitis C virus genotype 1a isolate Con1 harboring wild type NS3/4A protease infected in human HuH7 cells assessed as inhibition of HCV replicon replication by luciferase assay2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1071919Inhibition of Hepatitis C virus genotype 1b full-length NS3 protease assessed as equilibrium dissociation constant by surface plasmon resonance biosensor-based interaction kinetic analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID1698000Apparent permeability in dog MDCKII-LE cells at pH 7.4
AID1070609Ratio of AUC (0 to 24 hrs) in liver to plasma in Sprague-Dawley rat at 30 mg/kg, po by HPLC-MS/MS analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID664163Antiviral activity against Hepatitis C virus subtype 1b harboring protease A156V mutant by transient replicon assay2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID521279Antiviral activity against Hepatitis C virus genotype 1b N expressing NS3 A156T mutant infected in human HuH7 cells2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID1070645Inhibition of Hepatitis C virus genotype 5 NS3/4A protease using Ac-DE-Dap(QXL520)-EE-Abu-psi-[COO]-AS-Cys(5-FAMsp)-NH2 as substrate by FRET analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID656667Inhibition of Hepatitis C virus genotype 1a NS3/4A protease using Ac-DE-Dap(QXL520)-EE-Abu-psi-COO]-AS-C(5-FAMsp)-NH2 as substrate by FRET analysis2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease.
AID1698010Hepatic clearance in human administered through iv dosing
AID1070651Inhibition of Hepatitis C virus full-length NS3/4A protease assessed as quenched-fluorogenic RET-S1 substrate cleavage incubated for 10 mins prior to substrate addition by FRET analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID719469Antiviral activity against HCV subtype 1b expressing NS3/4A A156V mutant protease infected in ET cells after 72 hrs2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups.
AID664157Resistance index, ratio of EC50 for Hepatitis C virus subtype 1b harboring protease R155K mutant to EC50 for wild type Hepatitis C virus subtype 1b2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID1070646Inhibition of Hepatitis C virus genotype 4 NS3/4A protease using Ac-DE-Dap(QXL520)-EE-Abu-psi-[COO]-AS-Cys(5-FAMsp)-NH2 as substrate by FRET analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID521270Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 A156T mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID711499Inhibition of HCV 3a NS3 protease2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
AID664164Antiviral activity against Hepatitis C virus subtype 1b harboring protease A156T mutant by transient replicon assay2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID584101Ratio of EC50 for wild type HCV1b harboring NS3 protease gene to EC50 for HCV1b B13 harboring NS3 protease R26K, V46I, Q80L mutant2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.
AID1552078Binding affinity to HCV NS3/4a protease assessed as compound-protein adduct formation per mg protein using radiolabelled compound2019Bioorganic & medicinal chemistry letters, 08-15, Volume: 29, Issue:16
Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi
AID1071921Inhibition of Hepatitis C virus genotype 1a full-length NS3 protease assessed as equilibrium dissociation constant by surface plasmon resonance biosensor-based interaction kinetic analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID538709Antiviral activity against HCV genotype 1a transfected in human hepatoma cell assessed as inhibition of viral replication2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease.
AID521277Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 R155K mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells at >10 nM2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID1070619Metabolic stability in dog hepatocytes assessed as extraction ratio at 1 uM2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID664161Antiviral activity against Hepatitis C virus subtype 1b harboring protease D168V mutant by transient replicon assay2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID521269Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 V36M/R155K double mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID1070634Inhibition of CYP2D6 (unknown origin)2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID711494Ratio of drug level in liver to plasma of monkey2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
AID719468Antiviral activity against HCV subtype 1b expressing NS3/4A D168A mutant protease infected in ET cells after 72 hrs2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups.
AID1071920Inhibition of Hepatitis C virus genotype 1a full-length NS3/NS4A protease assessed as equilibrium dissociation constant by surface plasmon resonance biosensor-based interaction kinetic analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID719474Antiviral activity against HCV subtype 1a infected in human hepatoma cells2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups.
AID1070626Ratio of drug level in liver to plasma in rat2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1698011Fraction unbound in human plasma
AID1070637Inhibition of CYP1A2 (unknown origin)2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID711496Inhibition of HCV4 NS3 protease2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
AID664158Inhibition of HCV 1a protease 1a domain2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID711495Inhibition of HCV6 NS3 protease2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
AID521267Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 A156V mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID1070611AUC (0 to 24 hrs) in Sprague-Dawley rat liver at 30 mg/kg, po by HPLC-MS/MS analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID491860Inhibition of HCV NS3 protease by FRET assay2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents.
AID584108Ratio of EC50 for wild type HCV1b harboring NS3 protease gene to EC50 for HCV1b harboring NS3 protease T54S mutant2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.
AID1070627Ratio of drug level in liver to plasma in dog2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1070607Inhibition of Hepatitis C virus genotype 1a NS3/4A protease A156T mutant expressed in Escherichia coli BL21 (DE3) cells assessed as substrate cleavage using Ac-DE-Dap(QXL520)-EE-Abu-psi-[COO]AS-C(5-FAMsp)-NH2 as substrate by plate reader analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID656671Antiviral activity against Hepatitis C virus genotype 1b expressing NS3/4A protease A156S mutant infected in HuH7 cells2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease.
AID1299188Inhibition of full-length HCV genotype 1a NS3 protease R155K mutant using Ac-DED(Edans)EEAbu-psi-[COO]ASK(Dabcyl)-NH2 as substrate by FRET assay2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Discovery of pyrazinone based compounds that potently inhibit the drug-resistant enzyme variant R155K of the hepatitis C virus NS3 protease.
AID1070639Antiviral activity against Hepatitis C virus genotype 3 infected in human HuH7 cells assessed as decrease in replicon RNA level after 2 days by TaqMan Gold RT-PCR analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1070644Inhibition of Hepatitis C virus genotype 6 NS3/4A protease using Ac-DE-Dap(QXL520)-EE-Abu-psi-[COO]-AS-Cys(5-FAMsp)-NH2 as substrate by FRET analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID539677Antiviral activity against HCV 1a infected in human Huh-7 cells after 48hrs by luciferase assay2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease.
AID719470Antiviral activity against HCV subtype 1b expressing NS3/4A A156T mutant protease infected in ET cells after 72 hrs2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups.
AID1299187Inhibition of wild-type full-length HCV genotype 1a NS3 protease using Ac-DED(Edans)EEAbu-psi-[COO]ASK(Dabcyl)-NH2 as substrate by FRET assay2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Discovery of pyrazinone based compounds that potently inhibit the drug-resistant enzyme variant R155K of the hepatitis C virus NS3 protease.
AID612408Antiviral activity against HCV2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
P2-P1' macrocyclization of P2 phenylglycine based HCV NS3 protease inhibitors using ring-closing metathesis.
AID1070617Aqueous solubility of the compound at pH 7.4 by modified shake-flask method2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID584105Antiviral activity against HCV1b harboring Q80Q polymorphism in NS3 protease gene infected in human Huh7/Lunet cells assessed as inhibition of viral replication after 3 days by luciferase based transient-transfection assay2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.
AID711498Inhibition of HCV 2b NS3 protease2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
AID1299189Antiviral activity against HCV infected in human HuH7 cells by cell based replicon assay2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Discovery of pyrazinone based compounds that potently inhibit the drug-resistant enzyme variant R155K of the hepatitis C virus NS3 protease.
AID1698006Ratio of drug level in cynomolgus monkey blood to plasma administered through iv dosing by LC-MS/MS analysis
AID1070630Inhibition of human ERG at 10 uM2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1071912Inhibition of Hepatitis C virus genotype 1b full-length NS3/NS4A protease assessed as overall/observed affinity by surface plasmon resonance biosensor-based interaction kinetic analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID1645924Antiviral activity against HCV2019European journal of medicinal chemistry, Feb-15, Volume: 164A review on HCV inhibitors: Significance of non-structural polyproteins.
AID538711Clearance in Sprague-Dawley rat at 1 mg/kg, iv2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease.
AID1070624Ratio of drug level in liver to plasma in monkey2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID491861Antiviral activity against HCV 1B infected in human Huh7 cells by firefly luciferase reporter gene assay2010Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14
Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents.
AID1070633Inhibition of CYP3A4 (unknown origin)2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID521273Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 V36M mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID1070601Dissociation constant, pKa of the compound2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID711497Inhibition of HCV5 NS3 protease2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
AID1070608Inhibition of Hepatitis C virus genotype 1a wild type NS3/4A protease expressed in Escherichia coli BL21 (DE3) cells assessed as substrate cleavage using Ac-DE-Dap(QXL520)-EE-Abu-psi-[COO]AS-C(5-FAMsp)-NH2 as substrate by plate reader analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID539676Antiviral activity against HCV 1b infected in human Huh-7 cells after 48hrs by luciferase assay2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease.
AID584106Antiviral activity against HCV1b harboring Q80K polymorphism in NS3 protease gene infected in human Huh7/Lunet cells assessed as inhibition of viral replication after 3 days by luciferase based transient-transfection assay2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.
AID1070615Permeability from apical to basolateral side of human Caco2 cells2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1070642Inhibition of Hepatitis C virus genotype 3a NS3/4A protease using Ac-DE-Dap(QXL520)-EE-Abu-psi-[COO]-AS-Cys(5-FAMsp)-NH2 as substrate by FRET analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID521274Antiviral activity against wild-type Hepatitis C virus genotype 1b N infected in human Huh7 cells2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID664160Antiviral activity against Hepatitis C virus subtype 1a by stable replicon assay2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID1070603Antiviral activity against Hepatitis C virus harboring NS3/4A protease A156T mutant gene infected in human HuH7 cells assessed as inhibition of HCV subgenomic replicon replication after 72 hrs by ELISA2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1070614Efflux ratio of permeability from basolateral to apical side over apical to basolateral side in human Caco2 cells2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID521265Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 D168A mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID656674Antiviral activity against Hepatitis C virus genotype 1b expressing NS3/4A protease D158A mutant infected in HuH7 cells2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease.
AID664162Antiviral activity against Hepatitis C virus subtype 1b harboring protease D168A mutant by transient replicon assay2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID664165Antiviral activity against Hepatitis C virus subtype 1b harboring protease A156S mutant by transient replicon assay2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID1070643Inhibition of Hepatitis C virus genotype 2b NS3/4A protease using Ac-DE-Dap(QXL520)-EE-Abu-psi-[COO]-AS-Cys(5-FAMsp)-NH2 as substrate by FRET analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID719475Inhibition of HCV subtype 1a NS3/4A protease (Ac-DE-Dap(QXL520)-EE-Abu-psi-[COO]-ASC(5-FAMsp)-NH2 as substrate by FRET analysis2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups.
AID1070638Cytotoxicity against human MT4 cells2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID584107Ratio of EC50 for HCV1b harboring Q80K polymorphism in NS3 protease gene to EC50 for HCV1b harboring Q80Q polymorphism in NS3 protease gene2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.
AID1070610AUC (0 to 24 hrs) in Sprague-Dawley rat plasma at 30 mg/kg, po by HPLC-MS/MS analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID719473Antiviral activity against HCV subtype 1b infected in human hepatoma cells2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups.
AID538712AUC (0 to infinity) in Sprague-Dawley rat at 5 mg/kg, po2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease.
AID1645923Inhibition of HCV NS3/4a protease using Ac-DE-Dap(QXL520)-EE-Abu-shi-[COO]AS-C(5-FAMsp)-NH2 as substrate after 15 mins2019European journal of medicinal chemistry, Feb-15, Volume: 164A review on HCV inhibitors: Significance of non-structural polyproteins.
AID719467Antiviral activity against HCV subtype 1b expressing NS3/4A D168V mutant protease infected in ET cells after 72 hrs2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups.
AID711493Ratio of drug level in liver to plasma of rat2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.
AID1070628Oral bioavailability in monkey liver2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID664159Antiviral activity against Hepatitis C virus subtype 1b by stable replicon assay2012Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7
Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
AID1698009Hepatic clearance in cynomolgus monkey at < 1 mg/kg, iv administered as cassette dosing
AID1070623Lipophilicity, log D of the compound2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1070604Antiviral activity against Hepatitis C virus harboring wild type NS3/4A protease infected in human HuH7 cells assessed as inhibition of HCV subgenomic replicon replication after 72 hrs by ELISA2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID656675Antiviral activity against Hepatitis C virus genotype 1b expressing NS3/4A protease D158V mutant infected in HuH7 cells2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease.
AID521271Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 R155K mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID584104Ratio of EC50 for wild type HCV1b harboring NS3 protease gene to EC50 for HCV1b B10 harboring NS3 protease S7A, R26K, V48I, T54S mutant2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.
AID1070629Oral bioavailability in rat liver2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1070618Aqueous solubility of the compound at pH 1.2 by modified shake-flask method2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1070650Antiviral activity against Hepatitis C virus infected in human HuH7 cells assessed as inhibition of HCV subgenomic replicon replication after 72 hrs by ELISA2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID521275Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 T54A mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID656672Antiviral activity against Hepatitis C virus genotype 1b expressing NS3/4A protease A156T mutant infected in HuH7 cells2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Discovery of novel P3-oxo inhibitor of hepatitis C virus NS3/4A serine protease.
AID1071911Inhibition of Hepatitis C virus genotype 1b NS3 protease domain assessed as overall/observed affinity by surface plasmon resonance biosensor-based interaction kinetic analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID539675Oral bioavailability in rat2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease.
AID1698004Fraction unbound in cynomolgus monkey plasma
AID1070620Metabolic stability in cynomolgus monkey hepatocytes assessed as extraction ratio at 1 uM2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
AID1071910Inhibition of Hepatitis C virus genotype 3a full-length NS3 protease assessed as overall/observed affinity by surface plasmon resonance biosensor-based interaction kinetic analysis2014Journal of medicinal chemistry, Mar-13, Volume: 57, Issue:5
Identification of weak points of hepatitis C virus NS3 protease inhibitors using surface plasmon resonance biosensor-based interaction kinetic analysis and genetic variants.
AID521278Antiviral activity against Hepatitis C virus genotype 1b N expressing NS3 A156S mutant infected in human HuH7 cells2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID521272Selectivity ratio of EC50 for Hepatitis C virus genotype 1b N expressing NS3 R155Q mutant infected in human HuH7 cells to EC50 for Hepatitis C virus genotype 1b N expressing wild type NS3 infected in human HuH7 cells2008Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3
Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (76)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (2.63)29.6817
2010's63 (82.89)24.3611
2020's11 (14.47)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials30 (48.39%)5.53%
Trials0 (0.00%)5.53%
Reviews4 (6.45%)6.00%
Reviews2 (11.11%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational2 (3.23%)0.25%
Observational0 (0.00%)0.25%
Other26 (41.94%)84.16%
Other16 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]